Navigation Links
AVACEN Medical Engages Investment Banker
Date:12/22/2015

SAN DIEGO, Dec. 22, 2015 /PRNewswire/ -- AVACEN Medical today announced it has formally retained Objective Capital Partners, LLC to locate a qualified purchaser to acquire the Company.

Photo - http://photos.prnewswire.com/prnh/20151222/317765 
Logo - http://photos.prnewswire.com/prnh/20151222/317766LOGO

AVACEN Medical is a company involved in research and development related to medical devices designed to use its patented AVACEN Treatment Method. Its FDA-cleared AVACEN 100* product is a unique over-the-counter Class II medical device that addresses the medical needs of over one billion people worldwide. Developed over a 6 year period, the AVACEN 100 with over 3,000 firmware instructions is the world's first noninvasive family medical device that is designed to allow users to easily treat their entire body. The AVACEN 100 has a record of approximately 500,000 treatments without a single reported negative side effect.

According to Thomas G. Muehlbauer, CEO of AVACEN Medical, "Our patented AVACEN Treatment Method is an entirely new concept in microcirculation therapy. This is accomplished by safely and noninvasively increasing core body temperature by infusing heat into the palm of the hand. Almost everything that can go wrong with the body, including aging, can be traced to compromised microcirculation. Our device and patents address the alleviation of symptoms associated with an autoimmune, circulatory, neurological, lymphatic, thermoregulatory disorder, or endocrinal dysfunction, or any combination thereof."

He continued, "Of the alternatives we explored, the Company has determined it is in the best interest of its shareholders to offer itself as an acquisition target to a buyer that possesses the necessary resources to advance our fields of use and support the worldwide demand for the Company's products. We believe this is the most advantageous and quickest path to secure our $10 Billion annual sales potential while the 17 year average remaining term of our U.S. and International patents is most favorable."

AVACEN Medical recently announced that ClinicalTrials.gov, a service of the U.S. National Institutes of Health, has published the results of the Company's AVACEN Treatment Method clinical trials. The study was conducted by The University of California, San Diego and the Department of Veterans Affairs. The study results, published in the Society for Neuroscience (SfN) annual meeting and poster program indicate a major benefit for fibromyalgia sufferers using the AVACEN Treatment Method.  The data show a statistically significant reduction in widespread pain of over 40%, and a decrease in tender point count to a level below the value typically used for the clinical assessment of fibromyalgia.

Forward-looking statements:  During this process, management plans to continue to execute the Company's ongoing initiatives to bolster the position of its brand and business, but there can be no assurance of any transaction being entered into or consummated.  The Company has not set a timetable for completion of this process. The Company assumes no obligation to update any forward-looking statements contained in this news release as a result of new information or future events or developments.

About AVACEN Medical: Over the last two years, AVACEN Medical (www.AVACEN.com) has been awarded 3 U.S. and 5 International patents for its unique apparatus and methods that support its innovative medical process called the AVACEN Treatment Method. The company is dedicated to the innovation and design of safe, easy to use, noninvasive drug-free alternatives to treat chronic pain. Founded in 2009, AVACEN is headquartered in San Diego. Contact: Thomas Muehlbauer at (888) 4-AVACEN x 701 or email.

About Objective Capital Partners: Objective Capital Partners (www.objectivecp.com) is a leading M&A investment banking firm with over 500 successful transactions serving the transaction needs of growth stage and mid-size companies. The executive team has a unique combination of investment banking, private equity, and business ownership experience that enables Objective Capital Partners to provide large enterprise caliber investment banking services to companies with annual revenues up to $500 million.

*The AVACEN 100 is pending FDA approval for widespread pain related to fibromyalgia. It is FDA-Cleared as a Class II heat therapy system indicated for the temporary relief of minor muscle and joint pain and stiffness; the temporary relief of joint pain associated with arthritis, muscle spasms, minor strains and sprains; muscular relaxation. It is not available for sale for any non-cleared indication mentioned in this document.


'/>"/>
SOURCE AVACEN, Inc.
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. AVACEN Medical Patent Issued
2. AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode
3. Global Medical Devices Packaging Market Value of USD 30.5 Billion by 2020 - Analysis, Trends & Opportunities 2015-2020
4. Galil Medical Tender Offer to Acquire Perseon Corporation Expires
5. Hologic Applauds Passage of Federal Measures that Preserve Access to Mammography for Breast Cancer Screening and Increase Incentives for Biomedical Research and Development
6. Global Glaucoma Surgical Devices Market 2016-2020 - Leading Vendors are Alcon, Abbott Medical Optics, Carl Zeiss Meditec & Ellex Medical
7. CSL Behring Submits New Drug Application to Japans Pharmaceuticals and Medical Devices Agency for rIX-FP for Hemophilia B Patients
8. Varian Medical Systems Schedules First Quarter FY2016 News Release and Conference Call
9. Disposable Medical Device Sensors Market Worth 5,936 Million USD by 2020
10. Despite Push for Transparent Medical Records, 53% of Consumers Cant Access Electronic Health Data, HealthMine Survey Finds
11. Top 10 Medical Device Technologies Market 2015 by Type - Global Forecasts to 2020 for the $428 Billion Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform for ... the first annual edition of its Global CSR Risk and Performance Index. ... by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points ... ... ...
(Date:9/12/2017)...  ValGenesis Inc., the global leader in Enterprise ... announce the appointment of Dr. Ajaz Hussain ... Directors and Chairman of Advisory Board beginning September ... to manage their entire validation lifecycle process electronically ... process. Furthermore, ValGenesis VLMS enables rigorous compliance, helps ...
(Date:9/9/2017)... , Sept. 8, 2017 Dealmed Medical Supplies, ... supplier of medical equipment, supplies, drugs, vaccines, and specialty ... entered into an agreement to acquire Vantage Medical Supplies, ... in Holtsville, New York . ... supplying new and emerging medical practices, will operate under ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out ... free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting ... children of all ages; it is a non-competitive, non-timed event, which is all about ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in property taxes a year. In some states—like New York, New Jersey, Massachusetts, ... contrast, many overseas retirement havens have extremely low property-tax rates, which contributes to ...
Breaking Medicine News(10 mins):